PTCH1 biomarker and colorectal cancer
What is the PTCH1 biomarker?
The PTCH1 gene is a tumor suppressor gene that contains the instructions for making the patched-1 protein. The gene encodes a member of the patched family of proteins and is a component of the hedgehog signaling pathway.
How common is the PTCH1 mutation?
PTCH1 is altered in approximately 4 percent of colorectal cancer patients.
Some mutations are acquired during a person's lifetime and are present only in certain cells. These genetic changes, called somatic mutations, are not inherited.
What happens if I have the PTCH1 mutation?
Although there are no FDA approved therapies targeting PTCH1 mutations to date, there is a clinical trial investigating the efficacy of a potential treatment in cancer patients with PTCH1 Loss of Function mutations.
Other biomarkers
TMB BiomarkerTop resources
FDA approves Tecentriq for some people with stage III colon cancer
The FDA has approved Tecentriq (atezolizumab), given with chemotherapy after surgery, for people with stage III colon cancer whose tumors are mismatch repair deficient (dMMR). It’s the first immunotherapy approved for this use.
Does it matter where your colon cancer is located?
Understanding colon cancer sidedness is one more tool to help patients ask the right questions and advocate for the most effective treatment plan.
Bringing biomarker testing within reach: CLEAR for CRC to empower patients from day one
Biomarker testing can guide colorectal cancer treatment and improve outcomes. Learn how CLEAR for CRC is helping patients access this critical tool.